Biogen Inc Cmn (BIIB) 301.83 $BIIB Ionis Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Inc Cmn (BIIB) 301.83 $BIIB

Ionis Pharmaceuticals (IONS) Stock Surges 36% on Clinical Trial Success
Afrasiab Mian - Zacks Investment Research - Mon Aug 01, 1:04PM CDT
Shares of Ionis Pharmaceuticals (IONS) stock soared over 36% on Monday on news that the company's clinical drug trial for spinal muscular atrophy in infants was successful.
BIIB: 301.83 (+11.90), IONS: 38.01 (+8.82)

Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 5.08% Rise
Comtex SmarTrend(R) - Mon Aug 01, 11:49AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.06 to a high of $307.49. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $290.46 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 301.83 (+11.90)

SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 5.08% Gain
Comtex SmarTrend(R) - Mon Aug 01, 11:47AM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $299.06 to a high of $307.49. Yesterday, the shares gained 5.1%, which took the trading range above the 3-day high of $290.46 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 301.83 (+11.90)

What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 67.37 (+0.03), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), PFE: 37.31 (+0.42), SGNT: 21.68 (-0.01), ABBV: 66.94 (+0.71), PRTA: 56.66 (+1.61), NVS: 83.07 (-0.19)

Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy
BusinessWire - Mon Aug 01, 6:30AM CDT
---- Biogen Exercises Option to Develop and Commercialize Nusinersen Globally --
BIIB: 301.83 (+11.90), IONS: 38.01 (+8.82)

UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:15AM CDT
UCB (UCBJF) reported results for the first half of 2016.
BIIB: 301.83 (+11.90), AMGN: 174.16 (+2.13), NKTR: 17.76 (+0.47)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 7:02AM CDT
Amgen (AMGN) once again delivered a "beat and raise" quarter with growth products accounting for more than 50% of product sales.
BIIB: 301.83 (+11.90), INVA: 13.04 (+0.17), AMGN: 174.16 (+2.13), FMS: 45.65 (unch)

Vertex (VRTX) Posts Narrower Q2 Loss, Revenues Fall Short
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 6:13AM CDT
Although total revenues were just shy of expectations, Vertex's (VRTX) CF franchise sales improved sequentially.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), INVA: 13.04 (+0.17), ANIP: 61.06 (+0.46)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)

5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:36AM CDT
How will drug stocks like AMGN, GSK, VRTX and others, scheduled to report on Jul 27, fare this earnings season?
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), VRTX: 98.20 (+1.20), MDCO: 39.03 (-0.08), AMGN: 174.16 (+2.13), GSK: 45.25 (+0.18), ANIK: 50.64 (+0.72)

Fresh Research Reports For Intel (INTC), AT&T (T) & Others
Sheraz Mian - Zacks Investment Research - Mon Jul 25, 1:23PM CDT
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
BIIB: 301.83 (+11.90), RCI: 44.02 (-0.15), T: 43.18 (-0.11), PHM: 21.44 (+0.26), INTC: 34.85 (-0.01), SYK: 117.02 (+0.74)

Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 8:30AM CDT
Zacks Industry Outlook Highlights: Bristol-Myers, Pfizer, Sanofi, Amgen and Biogen
BIIB: 301.83 (+11.90), PFE: 37.31 (+0.42), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38), SNY: 42.49 (-0.14)

What's in Store for these 5 Drug Stocks in Q2 Earnings?
Arpita Dutt - Zacks Investment Research - Mon Jul 25, 7:24AM CDT
Medical stocks are once again expected be among the better performers in Q2. Johnson & Johnson (JNJ) and Biogen have already set the tone with beats and raised outlooks.
MDVN: 64.08 (+0.09), BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), ALDR: 30.79 (-1.31), SGEN: 49.22 (+1.16), NEO: 8.52 (-0.20), EXAS: 18.11 (+0.73)

Q2 Earnings Central Stays Busy, GM Sets New Record
Mark Vickery - ZACKS - Thu Jul 21, 4:07AM CDT
General Motors (GM) posted a record quarterly sales number and reached its first profit in the European market since 2011.
BIIB: 301.83 (+11.90), BX: 26.47 (-0.37), AXP: 64.13 (-0.33), QCOM: 61.85 (-0.73), GM: 31.30 (-0.24), INTC: 34.85 (-0.01), TRV: 116.81 (+0.59), LUV: 37.04 (+0.03)

SB5, An Adalimumab Biosimilar Referencing Humira(R), Accepted for Review by European Medicines Agency
BusinessWire - Sun Jul 17, 8:05PM CDT
--The approval of SB5 could make Biogen the first company to commercialize three anti-TNF biosimilar therapies in Europe
BIIB: 301.83 (+11.90)

Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Jul 15, 8:17AM CDT
Will Tecfidera scrips and sales recover enough to boost Biogen's (BIIB) performance in the second quarter?
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), LLY: 83.18 (+0.29), NVS: 83.07 (-0.19)

Biotech Stock Roundup: Juno In and Out of Clinical Hold, Amgen Biosimilar Gets Panel Backing
Arpita Dutt - Zacks Investment Research - Wed Jul 13, 2:17PM CDT
Immuno-oncology focused Juno (JUNO) remained in the news with the FDA first placing a clinical hold on a pivotal study and then removing it.
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), CYTR: 0.60 (-0.05), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), JUNO: 30.86 (-0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 206

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 193

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Lululemon Faces Class Action: Navigating Investor Impact

Updated Category News Views 138

Lululemon's Legal Storm: Understanding the Background If you thought the yoga gear game was all about stretch and flexibility, Lululemon Athletica, Inc (NASDAQ: LULU) just yanked us back to reality. The company finds itself in a legal tangle with its shareholders following a dismal performance report and a subsequent lawsuit. This situation has unfolded like a second-rate...

Continue Reading
Neil deGrasse Tyson Headlines HIMSS27 with Cosmic Insights

Updated Category News Views 237

celebrated science communicator, is set to close out the HIMSS27 conference with a keynote that's bound to leave a lasting impression. It's a fitting intersection of stars and stethoscopes, as the astrophysicist brings his expansive lens to the nitty-gritty of healthcare innovation. Splicing Science with Storytelling Folks, this ain't your standard healthcare gathering....

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 121

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 189

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading
Amdocs Faces a Storm: Investor Alert as Legal Probe Begins

Updated Category News Views 64

Amdocs' Recent Crisis: What Investors Need to Know Lately, it seems Amdocs Limited (NASDAQ: DOX) has found itself knee-deep in a situation that could make seasoned investors cringe. November shone some harsh light on the company's operations, a move that’s attracted attention from Schall, Brown & Schwartz LLP (“SBS”), a name not exactly foreign to shareholder...

Continue Reading

Top 5 Most Recently Viewed Articles

Cobre del Mayo Initiates Exchange Offer for New Notes

Updated Category News Views 154

Cobre del Mayo Launches Exchange Offer Cobre del Mayo, S.A. de C.V. ("CDM") has announced an exciting exchange offer aimed at providing opportunities for Eligible Holders. This initiative involves exchanging all outstanding Senior Secured PIK Toggle Notes due 2030 for new Senior Secured PIK Toggle Notes due in 2032. Understanding the Exchange Offer The exchange offer is...

Continue Reading
Valuable Michael Jordan Card Discovery Shakes Sports Collectors

Updated Category News Views 159

Remarkable Discovery of Michael Jordan Cards An extraordinary find of over 500 valuable Michael Jordan basketball cards has recently taken the sports world by storm. This discovery adds significant excitement to the sports card market, which has seen a resurgence in interest among collectors and enthusiasts alike. How the Collection Was Found The rare cards were unearthed...

Continue Reading
Foxconn Achieves Record Revenue Due to Strong AI Demand

Updated Category News Views 228

Foxconn's record third quarter performance hit the headlines back in 2024, with a staggering revenue of T$1.85 trillion ($57.3 billion). This marked a significant 20.2% surge from the previous year—one for the books, right? It not only eclipsed analyst estimates but also smashed Foxconn's own projections. You know these desks were buzzing after hearing those figures...

Continue Reading
Worlds Inc. Uplists to OTCQB, Enhancing Market Presence and Value

Updated Category News Views 69

Worlds Inc. Uplists to OTCQB for Enhanced Market Visibility Boston, MA — Worlds Inc. (OTCQB: WDDD) has reached an important milestone by moving up from the OTC Pink Market to the OTCQB Venture Market. This transition is set to improve trading visibility and liquidity, effective immediately. New Strategic Opportunities Ahead Thom Kidrin, the CEO of Worlds Inc., shared...

Continue Reading
Mercer International's Strong Q3 Performance and Dividend Update

Updated Category News Views 109

Mercer International Inc. Reports Third Quarter 2024 Results Selected Highlights Operating EBITDA for Q3 rose by 35% to $50.5 million (net loss of $17.6 million), up from $37.5 million (net loss of $26.0 million) year-over-year. Strength noted in softwood pulp markets. Pulp production was affected by unplanned downtime events. Quarterly cash dividend announced at $0.075

Continue Reading